Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
作者： Mitsuaki Ohkoudo , Hiroki Sawa , Mitsuhiro Hara , Kazuhiko Saruta , Toshiko Aiso
关键词:
摘要: Association of p53 gene abnormalities with tumor progression and prognosis many neoplasms has been demonstrated, but little is known about the clinical significance in meningiomas. The protein expression recurrent meningiomas its relationships MDM2 proliferation activity were investigated by analyzing 39 immunohistochemically. was expressed 11 (35%) 31 non-recurrent 7 (88%) 8 A high frequency observed meningiomas, which tended to have a positive index (p53 PI), indicating that immunoreactivity may be marker for predicting recurrence. Four PIs analyzed polymerase chain reaction-single strand conformation polymorphism method detect mutations, none found exons 4-8 this gene. Fifteen (71%) 21 MDM2-positive 3 (17%) 18 MDM2-negative tumors protein, showing more common expression. absence mutation indicate stabilization wild type through interaction protein. Ki-67/MIB-1 (MIB-1 PI) correlated well p53-positive had significantly higher mean MIB-1 PI than p53-negative tumors, suggesting wild-type inactivation involved controlling proliferative In conclusion, immunohistochemical examination as help predict malignant potential
springer.com
sci-hub.se 参考文章(34)
Girod Sc, Fischer U, Krueger Gr, Cesarz D, Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Research. ,vol. 15, pp. 1453- 1457 ,(1995)
A. Zauberman, Y. Barak, N. Ragimov, N. Levy, M. Oren, Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. The EMBO Journal. ,vol. 12, pp. 2799- 2808 ,(1993) , 10.1002/J.1460-2075.1993.TB05941.X
Steffen Albrecht, J. Clay Goodman, Sri Rajagopolan, Moise Levy, David A. Cech, Linda D. Cooley, Malignant meningioma in Gorlin's syndrome: cytogenetic and p53 gene analysis: Case report Journal of Neurosurgery. ,vol. 81, pp. 466- 471 ,(1994) , 10.3171/JNS.1994.81.3.0466
Y. Barak, T. Juven, R. Haffner, M. Oren, mdm2 expression is induced by wild type p53 activity. The EMBO Journal. ,vol. 12, pp. 461- 468 ,(1993) , 10.1002/J.1460-2075.1993.TB05678.X
J Chen, V Marechal, A J Levine, Mapping of the p53 and mdm-2 interaction domains. Molecular and Cellular Biology. ,vol. 13, pp. 4107- 4114 ,(1993) , 10.1128/MCB.13.7.4107
Takashi Tokino, Takashi Tokino, Bert Vogelstein, Kenneth W. Kinzler, David Sidransky, David E. Hill, Jonathan D. Oliner, Sharon Smith, Marilee Burrell, Fredrick S. Leach, Paul Meltzer, p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas Cancer Research. ,vol. 53, pp. 2231- 2234 ,(1993)
Jonathan D. Oliner, Jennifer A. Pietenpol, Sam Thiagalingam, Jeno Gyuris, Kenneth W. Kinzler, Bert Vogelstein, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature. ,vol. 362, pp. 857- 860 ,(1993) , 10.1038/362857A0
E Jaros, RH Perry, L Adam, PJ Kelly, PJ Crawford, RM Kalbag, AD Mendelow, RP Sengupta, ADJ Pearson, Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. British Journal of Cancer. ,vol. 66, pp. 373- 385 ,(1992) , 10.1038/BJC.1992.273
J Marx, How p53 suppresses cell growth Science. ,vol. 262, pp. 1644- 1645 ,(1993) , 10.1126/SCIENCE.8259506
Masaru Ohta, Tom Iwaki, Tetsuyuki Kitamoto, Iwao Takeshita, Jun Tateishi, Masashi Fukui, MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management Cancer. ,vol. 74, pp. 3176- 3189 ,(1994) , 10.1002/1097-0142(19941215)74:12<3176::AID-CNCR2820741217>3.0.CO;2-N